Stratus Therapeutics
Gurinder Singh is a Senior Scientist at Garuda Therapeutics with experience in utilizing CRISPR/Cas9 for generating hypoimmunogenic iPSC cells for cellular therapy. Previously, Gurinder worked at Morsani College of Medicine, Boston Children's Hospital, Harvard Medical School, and University of Houston in various research roles focused on congenital heart diseases, endothelial dysfunction, atherosclerosis, and diabetes associated cardiac hypertrophy. Gurinder holds a PhD in Biotechnology and Epigenetics from Post Graduate Institute of Medical Education and Research.
This person is not in any offices
Stratus Therapeutics
4 followers
Stratus Therapeutics is redefining regenerative medicine with Stratus Prime™ — a platform for full hematopoietic system renewal, on demand. Our proprietary product, ST-101, includes both hematopoietic stem cells (Prime HSCs™) and hematopoietic progenitor cells (Prime HPCs™) to drive durable, long-term engraftment with full hematopoietic system restoration, while supporting near-term immune reconstitution.